Budesonide/formoterol improves exercise tolerance compared with placebo and formoterol in COPD patients Source: Annual Congress 2009 - Influence of interventions and comorbidity on exercise performance Year: 2009
Metronome-paced hyperventilation, CT measurements and exercise to investigate dynamic hyperinflation contrasting tiotropium versus indacaterol treatment in moderate COPD patients Source: International Congress 2015 – Unravelling the mechanisms of symptoms and exercise limitationas in disease Year: 2015
Effects of inhaled formoterol on dynamic hyperinflation during and after incremental treadmill exercise in patients with advanced COPD Source: Eur Respir J 2006; 28: Suppl. 50, 172s Year: 2006
The effects of adding in erdosteine on the routine bronchodilator therapy in moderate and severe COPD patients Source: Annual Congress 2006 - COPD therapy Year: 2006
Once-daily tiotropium Respimat add-on therapy improves lung function and asthma control in moderate symptomatic asthma, independent of baseline characteristics Source: International Congress 2017 – Clinical points to ponder in asthma Year: 2017
Pre-exercise inhalation of short-acting ß-agonists (SABA) safely improves exercise performance in severe COPD patients by reducing lung hyperinflation Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010
Once-daily tiotropium Respimat add-on therapy improves lung function in children with moderate symptomatic asthma, independent of the degree of airflow obstruction Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017
Increased respiratory symptoms in COPD patients on withdrawal of therapy: evidence of long-term efficacy gains with formoterol turbuhaler Source: Eur Respir J 2002; 20: Suppl. 38, 243s Year: 2002
Effects of supplemental oxygen and high-dose inhaled bronchodilator therapy in exercise performance and dyspnoea in patients with stable COPD Source: Annual Congress 2004 - Exercise and systemic effects in COPD Year: 2004
QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015
Effects of tiotropium on neurohumoral activation during exercise in stable COPD patients Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Bronchodilator efficacy of tiotropium in patients with mild COPD Source: Eur Respir J 2006; 28: Suppl. 50, 616s Year: 2006
Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
Effect of oral sildenafil on physiological and sensory response to exercise in patients with mild-to-moderate COPD Source: Virtual Congress 2020 – Respiratory diseases, hypoxia and cardiovascular function Year: 2020
The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 240s Year: 2002
Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Effects of tiotropium and salmeterol/fluticasone combination on lung hyperinflation, dyspnea and exercise tolerance in COPD Source: Eur Respir J 2006; 28: Suppl. 50, 33s Year: 2006
Patients with moderate asthma symptoms may benefit from short-term inhaled corticosteroid monotherapy Source: Eur Respir J 2007; 30: Suppl. 51, 615s Year: 2007
Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007